David N. Gordon - 01 Jun 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
01 Jun 2021
Net transactions value
-$1,142,375
Form type
4
Filing time
02 Jun 2021, 21:49:08 UTC
Next filing
07 Jul 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +87,500 +81% 195,992 01 Jun 2021 Direct F1
transaction ACRS Common Stock Sale $207,024 -9,115 -4.7% $22.71 186,877 01 Jun 2021 Direct F2, F3
transaction ACRS Common Stock Sale $115,142 -4,885 -2.6% $23.57 181,992 01 Jun 2021 Direct F2, F4
transaction ACRS Common Stock Sale $668,808 -31,114 -17% $21.50 150,878 02 Jun 2021 Direct F5, F6
transaction ACRS Common Stock Sale $151,401 -6,800 -4.5% $22.26 144,078 02 Jun 2021 Direct F5, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -87,500 -100% $0.000000* 0 01 Jun 2021 Common Stock 87,500 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.24 to $23.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.33 to $23.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
F6 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.01 to $21.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.01 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.